Horizon, CareDx enter into OEM agreement, 2/17

Create PDF

February 2017—Horizon Discovery Group has entered into an original equipment manufacturer agreement with CareDx. Under the terms of the new agreement, Horizon will supply cell-free DNA-based molecular reference standards for inclusion in CareDx’s cfDNA testing workflows for monitoring transplanted organ rejection.

The agreement is an extension of a previously announced collaboration for the development of HDx cell-free reference standards to support proficiency testing of CareDx’s solid organ transplant injury monitoring test, Allo­Sure. Future agreements between the two companies are expected.

Horizon Discovery Group, +44 (0) 1223 976 000